• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Interim Chief Financial Office Jung Joel R

    6/13/24 4:15:05 PM ET
    $RNLX
    Medical Specialities
    Health Care
    Get the next $RNLX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Jung Joel R

    (Last) (First) (Middle)
    C/O RENALYTIX PLC
    2 LEMAN STREET

    (Street)
    LONDON X0 E1W 9US

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Renalytix plc [ RNLX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Interim Chief Financial Office
    3. Date of Earliest Transaction (Month/Day/Year)
    06/11/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (right to buy) $0.2067(1) 06/11/2024 A 60,000 (2) 06/10/2034 Ordinary Shares 60,000 $0 60,000 D
    Explanation of Responses:
    1. The exercise price is 0.1625 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.2067 using the Bank of England rate as of June 10, 2024 (1.00 pound sterling = $1.272).
    2. One fourth (1/4th) of the shares subject to the option award shall vest on August 28, 2024, and the remaining shares shall vest in nine equal monthly installments thereafter, subject to the Reporting Person's continuous service.
    /s/ Katie Kazem, Attorney-in-Fact 06/12/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RNLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RNLX

    DatePrice TargetRatingAnalyst
    1/18/2022$30.00Buy
    HC Wainwright & Co.
    1/4/2022$24.00Buy
    BTIG
    10/4/2021$28.00Buy
    Guggenheim
    7/2/2021$38.00Buy
    Berenberg
    More analyst ratings

    $RNLX
    Financials

    Live finance-specific insights

    See more
    • Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024

      LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024. The Company made continued progress towards commercial adoption with inclusion of KidneyIntelX in clinical guidelines, issuance of a Medicare coverage draft, performance of new direct to physician sales force, April launch of U.S. Food and Drug Administration ("FDA") De Novo authorized kidneyintelX.dkd, and release of new real

      5/15/24 7:00:14 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15

      LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day. Conference Call Details:To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to joi

      5/9/24 7:00:12 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024

      LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) (the "Company"), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023. The Company plans to issue another announcement following today's report of financial results regarding the date and time of its conference call and webcast to discuss second quarter financial results and other key events. The Company made significant progress during the quarter in revenue generation, reimbursement coverage, the publication of real-world evidence

      2/15/24 7:00:32 AM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Renalytix plc

      DEF 14A - Renalytix plc (0001811115) (Filer)

      10/11/24 4:36:26 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form PRE 14A filed by Renalytix plc

      PRE 14A - Renalytix plc (0001811115) (Filer)

      10/1/24 5:14:50 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix plc filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

      8-K - Renalytix plc (0001811115) (Filer)

      10/1/24 5:12:55 PM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Renalytix with a new price target

      HC Wainwright & Co. initiated coverage of Renalytix with a rating of Buy and set a new price target of $30.00

      1/18/22 6:09:55 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • BTIG initiated coverage on Renalytix with a new price target

      BTIG initiated coverage of Renalytix with a rating of Buy and set a new price target of $24.00

      1/4/22 6:53:29 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Guggenheim initiated coverage on Renalytix with a new price target

      Guggenheim initiated coverage of Renalytix with a rating of Buy and set a new price target of $28.00

      10/4/21 8:16:45 AM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $RNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13D/A filed by Renalytix plc

      SC 13D/A - Renalytix plc (0001811115) (Subject)

      10/2/24 8:05:02 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by Renalytix plc (Amendment)

      SC 13D/A - Renalytix plc (0001811115) (Subject)

      4/26/24 4:01:17 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Renalytix plc

      SC 13G - Renalytix plc (0001811115) (Subject)

      4/4/24 10:15:51 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Interim Chief Financial Office Jung Joel R

      4 - Renalytix plc (0001811115) (Issuer)

      6/13/24 4:15:05 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Jung Joel R

      3 - Renalytix plc (0001811115) (Issuer)

      6/5/24 4:17:02 PM ET
      $RNLX
      Medical Specialities
      Health Care
    • Icahn School Of Medicine At Mount Sinai acquired $2,340,094 worth of Ordinary Shares (9,360,374 units at $0.25) (SEC Form 4)

      4 - Renalytix plc (0001811115) (Issuer)

      4/26/24 4:01:47 PM ET
      $RNLX
      Medical Specialities
      Health Care

    $RNLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

      LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with type 2 diabetes and chronic kidney disease, announces the appointment of Howard Doran as Chief Business Officer, effective September 1, 2023. Mr. Doran's primary responsibility will be leading the KidneyIntelX global sales effort. He is a senior executive with over 30 years of diversified general management, strategic planning, and marketing/sales experience in the diagnostics and pharmaceutical industries in domestic and international markets. Mr. Doran serv

      9/7/23 7:00:27 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors

      LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the appointment of Catherine Coste to the Company's Board of Directors, effective June 30, 2023. Ms. Coste was also appointed as the Non-Executive Chair of the Audit Committee and a member of the Renumeration Committee. Ms. Coste has extensive financial experience having retired from Deloitte and Touche LLP ("Deloitte") in 2020, where she was a senior partner and served as one of Deloitte's life sciences

      7/3/23 7:00:00 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors

      PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc

      5/12/22 1:00:00 PM ET
      $AERC
      $NVCR
      $PODD
      $RNLX
      Environmental Services
      Utilities
      Medical/Dental Instruments
      Health Care

    $RNLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Commencement of trading on OTCQB in the United States

      LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB:RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that as previously disclosed regarding its intention to move listing of its American Depository Shares ("ADSs") from Nasdaq to the OTC Markets Group Inc., that effective with the market open today its ADSs are now trading on the OTCQB. The Directors have considered the benefits of the Nasdaq listing against the cost of maintaining the listing and have decided to downlist the ADSs from Nasdaq, and a

      10/8/24 7:00:00 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US

      LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno'), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD). The initial focus of the collaboration will be on developing a roadmap for implementation of KidneyIntelX at the Steno Diabetes Center and affiliated practices. Through this collaboration Renalytix and Steno will in

      7/11/24 7:00:03 AM ET
      $RNLX
      Medical Specialities
      Health Care
    • Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination

      LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the "Panel"), which request has now stayed the suspension of the Company's securities pending the Panel's decision as described below. Throughout the hearings process, pending the Panel's decision, the Company's American Depositary Shares ("ADSs") will continue trading on The Nasdaq Global Market under the symbol "RNLX." At the Panel hearing, the Company intends to present a strategic plan to regain compliance with the applicable Nasdaq listing requirements. However, there can be no assurance that the Comp

      6/27/24 6:30:18 PM ET
      $RNLX
      Medical Specialities
      Health Care